Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug screening targeting TREM2-TYROBP transmembrane binding

5 May 2025

Abstract excerpt

TREM2 encodes a microglial membrane receptor involved in the disease-associated microglia (DAM) phenotype whose activation requires the transmembrane interaction with TYROBP. Mutations in TREM2 represent a high-impact risk factor for Alzheimer's disease (AD) which turned TREM2 into a significant drug target. We present a bacterial two-hybrid (B2H) system designed for high-throughput screening of modulators for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Medicinal Plants and Neuroprotection
Share to Neuroinflammation and Neurodegeneration Mechanisms
Share to Pharmacological Effects of Natural Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40325411
DOI: 10.1186/s10020-025-01229-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug screening targeting TREM2-TYROBP transmembrane bindingPMID 40325411Read ↗

Drug screening targeting TREM2-TYROBP transmembrane bindingSemantic proximity Read ↗

AI-Assisted Discovery and Optimization of Small Molecule TREM2 Agonists with Functional Microglial ActivitySemantic proximity Read ↗

TREM2 Activation by First-in-Class Direct Small Molecule Agonists: DEL Screening, Optimization, Biophysical Validation, and Functional CharacterizationSemantic proximity Read ↗

Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer’s ModelsSemantic proximity Read ↗

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligandsSemantic proximity Read ↗

Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple AD ligandsSemantic proximity Read ↗

Computational saturation mutagenesis to explore the effect of pathogenic mutations on extra-cellular domains of TREM2 associated with Alzheimer's and Nasu-Hakola disease.Semantic proximity Read ↗

Evaluating the pathogenicity, stability, and stereochemical effects of variants of unknown significance in TREM2 using orthogonal structural analysesSemantic proximity Read ↗

Aβ-Overlapping Ectodomain Binding of the Clinical-Stage TREM2 Agonist VG-3927Semantic proximity Read ↗

AI-Guided Design of Cyclic Peptide Binders Targeting TREM2 Using CycleRFdiffusion and Experimental ValidationSemantic proximity Read ↗

Selection and structural characterisation of anti-TREM2 scFvs that reduce levels of shed ectodomainSemantic proximity Read ↗

Building a potent TREM2 agonistic, biparatopic, common light chain antibodySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.